Trial Profile
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Pinatuzumab vedotin (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Genentech
- 06 Sep 2016 Safety and pharmacokinetic results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 10 Mar 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 10 Mar 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.